Search results
-
A cancer pipeline cull from AbbVie
… the latter, also on top of Jakafi, didn’t impress at ASH 2023. And the SHP inhibitor JAB-3312, originated by …
- 02/06/2024 - 13:49 -
Car-T comes full circle
… (10/50 pts) in ph1/2 Transcend CLL 004 *, presented at ASH 2023 GLPG5201 Galapagos Autologous … 57% CRR (8/14 pts) in ph1 portion, presented at ASH 2023 Cemacabtagene ansegedleucel Allogene … recent data from the Transcend CLL 004 trial, presented at ASH 2023, showed a 20% complete response rate among a …
- 01/19/2024 - 16:00 -
Merck’s latest move is in bispecifics
… The latest update from a phase 1 study of the project, at ASH 2023, found a 63% response rate in relapsed/refractory …
- 06/19/2024 - 16:48 -
A new order in BTK inhibition
… one responder had a C481S BTK mutation Source: ASH 2023. Conferences Trial …
- 01/02/2024 - 15:04 -
ASH 2023 – Sympatico gives Imbruvica a second chance
ASH 2023 – Sympatico gives Imbruvica a second chance …
- 12/15/2023 - 13:39 -
ASH 2023 movers – an unexpected comeback for MorphoSys
ASH 2023 movers – an unexpected comeback for MorphoSys …
- 12/18/2023 - 14:37 -
ASH 2023 – Genmab's son of Darzalex in focus
ASH 2023 – Genmab's son of Darzalex in focus … development of GEN3014 . GEN3014 safety data at ASH 2023 Source: Dr Sebastian Grosicki & ASH. …
- 12/15/2023 - 13:39 -
ASH 2023 – Arcellx still hopes to challenge Carvykti
ASH 2023 – Arcellx still hopes to challenge Carvykti …
- 12/14/2023 - 17:01 -
ASH 2023 – the markets forgive MorphoSys
ASH 2023 – the markets forgive MorphoSys …
- 04/26/2024 - 15:06 -
ASH 2023 – Regeneron defends its bispecifics
ASH 2023 – Regeneron defends its bispecifics …
- 12/12/2023 - 05:08
